

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **The United Laboratories International Holdings Limited**

**聯邦制藥國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 3933)

### **UPDATED INFORMATION OF THE GROUP'S PRODUCTS**

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that on 29 June 2021, Zhuhai United Laboratories Co., Ltd. (珠海聯邦制藥股份有限公司) ("Zhuhai United Laboratories"), a wholly-owned subsidiary of the Company, received the certificate of clinical trial approval (Approval No.: CXSL2101157) issued by the National Medical Products Administration regarding Semaglutide Injection applied by Zhuhai United Laboratories.

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) analogue for the treatment of type 2 diabetes. By promoting the secretion of insulin by pancreatic cells, it can significantly reduce the blood glucose in vivo, reduce the weight of the patients and show obvious cardiovascular benefits. Semaglutide is the most effective blood-glucose-reduction GLP-1 analogue among the same target drugs existing in the market. It only requires to be injected once a week, and is characterized by safety, simplicity and significant efficacy. In addition to the indication of type 2 diabetes, several indications including weight loss, non-alcoholic steatohepatitis (NASH) and Alzheimer's disease are currently under research.

As the first-to-market generic pharmaceutical enterprise applying for the clinical trial of Semaglutide as a biosimilar drug, the Company will continue to commit itself to the research and development of new products, and focus on enhancing its competitiveness and creativity in the biopharmaceutical industry, with a view of creating greater benefits for the Company and its shareholders.

By Order of the Board

**The United Laboratories International Holdings Limited**

**Tsoi Hoi Shan**

*Chairman*

Hong Kong, 30 June 2021

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.